ONTX - Onconova Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-9.057M

Cash

34.22M

Avg Qtr Burn

-4.135M

Short % of Float

1.40%

Insider Ownership

0.46%

Institutional Own.

7.41%

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Rigosertib Details Cutaneous squamous cell carcinoma, Solid tumor/s, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Narazaciclib w/ letrozole Details Solid tumor/s, Cancer, Endometrial cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rigosertib (RAS inhibitor) + Nivolumab + pembrolizumab Details Non-small cell lung carcinoma, Cancer, Cutaneous squamous cell carcinoma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Narazaciclib (ON 123300) (CDK4/6 & ARK5 inhibitor) Details Solid tumor/s, Cancer, Breast cancer, ER+/HER2- breast cancer, Metastatic breast cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rigosertib Details Myelodysplastic syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.